New cocktail of four drugs hopes to tackle tough lymphoma

NCT ID NCT07418190

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of four drugs (zanubrutinib, rituximab, lenalidomide, and tislelizumab) in 33 people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see how many patients achieve a complete response after six cycles of therapy. Those who respond will continue on a maintenance regimen for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib, rituximab, lenalidomide, and tislelizumab
What this could lead to: If successful, this combination could offer a new treatment option for patients with follicular lymphoma that has come back or not responded to prior therapies.
What could go wrong: This is a small, early-phase trial (33 people) with no comparison group. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.